Back to results
US 2026/0176308 A1Published application
Method of producing transduction particles
AssigneeSNIPR Biome ApS
InventorSzabolcs SEMSEY
Life of this patent
Estimating the term…
Abstract
The invention relates to the production of transduction particles, such as phage, as well as compositions comprising the particles and use of these. The particles are particularly useful for delivering toxic payloads into target bacteria for antibacterial action. The invention is also useful for the production of wild-type (“native”) phage and phage cocktails comprising different types of phage. Embodiments enable production of compositions of such particles for use in medical, environmental or food production settings.
Claims20
1:
- A composition comprising transduction particles which are capable of recognizing a receptor on bacterial target cells for transduction of the bacterial target cells, wherein the transduction particles are obtained or obtainable by a production method comprising producing the particles in bacterial producer cells, wherein the bacterial producer cells do not express the receptor on their surface, and wherein the production yield of transduction particles is enhanced compared to production in bacterial producer cells that express the receptor on their surface.
2:
- A composition comprising transduction particles which are capable of recognizing a receptor on bacterial target cells for transduction of the bacterial target cells, wherein the composition is produced by a production method comprising producing the transduction particles in bacterial producer cells, wherein the bacterial producer cells do not express the receptor on their surface, and wherein the production yield of transduction particles is enhanced compared to production in bacterial producer cells that express the receptor on their surface.
3:
- The composition according to claim 1, wherein the composition comprises no producer cell LPS.
4:
- The composition of claim 1, wherein the transduction particles comprise a phage capsid, wherein the capsid comprises a packaged nucleic acid of interest (NSI) for transduction into the target bacterial cells.
5:
- The composition of claim 4, wherein the NSI comprises or encodes an antibacterial agent that kills the bacterial target cells, or wherein the NSI comprises or encodes a component of such an agent.
6:
- The composition of claim 5, wherein the NSI comprises a nucleotide sequence encoding a guide RNA of a CRISPR/Cas system.
7:
- The composition of claim 1, wherein the transduction particles are phages.
8:
- The composition of claim 1, wherein the transduction particles are non-self-replicative.
9:
- The composition of claim 1, wherein the receptor comprises an LPS.
10:
- The composition of claim 1, wherein the bacterial target cells are selected from the group consisting of Escherichia cells, Klebsiella cells, Clostridium cells, Pseudomonas cells, E. coli cells, K. pneunoniae cells, C. dificile cells, and P. aeruginosa cells.
11:
- The composition of claim 1, wherein the transduction particles comprise a P2 phage capsid and the receptor is a P2 receptor.
12:
- The composition according to claim 2, wherein the composition comprises no producer cell LPS.
13:
- The composition of claim 2, wherein the transduction particles comprise a phage capsid, wherein the capsid comprises a packaged nucleic acid of interest (NSI) for transduction into the target bacterial cells,
- optionally, wherein the NSI comprises or encodes an antibacterial agent that kills the bacterial target cells, or wherein the NSI comprises or encodes a component of such an agent, and
- optionally, wherein the NSI comprises a nucleotide sequence encoding a guide RNA of a CRISPR/Cas system.
14:
- The composition of claim 2, wherein the transduction particles are phages.
15:
- The composition of claim 2, wherein the transduction particles are non-self-replicative.
16:
- The composition of claim 2, wherein the receptor comprises an LPS.
17:
- The composition of claim 2, wherein the bacterial target cells are selected from the group consisting of Escherichia cells, Klebsiella cells, Clostridium cells, Pseudomonas cells, E. coli cells, K. pneumoniae cells, C. dificile cells, and P. aeruginosa cells.
18:
- The composition of claim 2, wherein the transduction particles comprise a P2 phage capsid and the receptor is a P2 receptor.
19:
- A method of treating a disease or condition in a human or animal subject, wherein the disease or condition is mediated by bacterial target cells, the method comprising administering the composition of claim 1 to the subject, whereby the bacterial target cells are killed or the growth or proliferation of the bacterial target cells is inhibited, thereby treating the disease or condition.
20:
- A method of killing bacterial target cells, the method comprising contacting the bacterial target cells with the composition according to claim 1, wherein transduction particles infect the cells and introduce therein a NSI, wherein the NSI comprises or encodes an antibacterial agent that kills the bacterial target cells, or wherein the NSI comprises or encodes a component of such an agent.